SUMMIT THERAPEUTICS PLC AMERICA (SMMT) Covered Calls

You can sell covered calls on SUMMIT THERAPEUTICS PLC AMERICA to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for SMMT (prices last updated Fri 4:16 PM ET):

SUMMIT THERAPEUTICS PLC AMERICA (SMMT) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
1.88 +0.03 1.85 2.00 7K 1.0 0.0B
Covered Calls For SUMMIT THERAPEUTICS PLC AMERICA (SMMT)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Nov 16 2.5 0.00 2.00 0.0% 0.0%
Jan 18 2.5 0.10 1.90 5.3% 21.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom